^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm). Add to Collection

Published date:
05/19/2021
Excerpt:
Cohort C: 36 pts with OTHERm only, any receptor subtype, treated with ALP in any combination....In Cohort C, rwPFS > 6 months was observed in 5 pts bearing: N345K, Q75E, R38C, G106_108del, and N345K/N1044K....there is evidence that OTHERm may differ in their degree of PI3K activation, oncogenicity, and ALP sensitivity.
DOI:
10.1200/JCO.2021.39.15_suppl.1068